Urothelial Cancer Drugs Market

Urothelial Cancer Drugs Market Outlook 2031

The global urothelial cancer drugs market size was valued at USD 2.93 Billion in 2022 and is projected to reach USD 18.74 Billion by 2031, expanding at a CAGR of 22.9% during the forecast period, 2023–2031. The growth of the market is attributed to the existence of a strong pipeline, availability of novel drugs, and growing incidence of urothelial cancer among the rising geriatric population.

Additionally the changed lifestyle and rising public awareness are major driving factors for the market growth. A type of tumor formation in the bladder is called as urothelial carcinoma and is also known as transitional cell carcinoma. It is a type of malignant neoplasm arising from urothelium that can affect other parts of the body without proper treatment and therapy.

Get Free Sample Report

The urothelium is inner lining of the urethra, bladder, and ureters. The cancer type is broadly classified into three classes: the early stage or non-muscle invasive bladder cancer (NMIBC), the mid-stage or muscle-invasive bladder cancer disease (MIBC), and the late-stage called metastatic disease. As per a global health report, about 70% of patients are of NMIBC, 20% are of the MIBC, and 10% at the late stage.

As per Globocan 2020, the disease ranks as 10th most common malignancy disease worldwide, with around 2.4 million cases and 419,000 newly detected patients recorded every year. Bladder urothelial carcinoma is responsible for nearly 90% of all urinary cancer patients.

According to the report of the International Agency for Research on Cancer (IARC), 60% of all bladder cancer cases are witnessed in developed countries such as the US and some countries of Europe while Belgium tops the list with the highest number of bladder cancer cases.

The COVID-19 pandemic has had an intense impact on the urothelial cancer drugs market. According the statistics reported by the National Health Services, England in 2020, on topic 'NHS Diagnostic Waiting Times and Activity Data', the healthcare facilities of the cancer treatment had been shattered worldwide due to the rising shift of the pharmaceutical companies to solve huge burden of COVID-19 pandemic at the first place.

Cancer patients are witnessing several concerns such as increase of the waiting time for cancer diagnostic procedures in hospitals and clinics. In August 2020, around 50% of cases in England for cystoscopy was forced to wait for minimum of six weeks against the 9% in 2019. This great impact in diagnosis showed negative impact on the treatment of the disease as well.

Urothelial Cancer Drugs Market Trends, Drivers, Restraints, and Opportunities

• Surging numbers of cases suffering from urothelial cancer and large recurrence rate of patients among geriatric population across the world are major driving factors for the market.
• Increasing awareness among the population and initiatives by government and non-government organizations for early diagnosis of cancer are propelling the market growth.
• High number of new drug approvals in the field along with large funding for the research and development activities presents a major factor for the overall market growth.
• Availability of significant number of generic drugs in the market and high expenditure on R&D are proving to be major restraints to the market.
• Rising concerns related to the side effects associated with chemotherapy is a challenge that can hamper the market expansion in the coming future.
• Advanced technology for the development of new drugs is offering great opportunities for the market in the near future.

Scope of Urothelial Cancer Drugs Market Report

The report on the global urothelial cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Urothelial Cancer Drugs Market Segment Insights

Treatments Segment Analysis

Based on treatments, the global urothelial cancer drugs market is bifurcated into chemotherapy and immunotherapy. The chemotherapy segment is expected to grow at a considerable pace during the forecast period considering the factors that the chemotherapy can be used alone as well as in the combination therapy when needed.

Chemotherapy is used to reduce or stop the development of cancer cells and is the most commonly adopted form of treatment. The treatment works on the whole body to damage and destroy cancer cells so that the spread of cancer cells to the other parts of the body can be prevented.

The rising approvals of new drugs is a significant driver for the segment. For example, the United States Food and Drug Administration (FDA) approved Padcev, which was developed by Astellas Pharma US Inc. coupled with Seattle Genetics Inc. in December 2019.

The immunotherapy segment, however, is projected to register substantial growth in the coming years owing to the high research and development in the field as well as the positive results of the clinical trials of the treatment technique.

Get Free Sample Report

Regional Outlook

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to dominate the market during the forecast period owing to the factors including availability of large targeted patients, increased drug approvals, adoption of novel therapeutics, and high funding in the region.

According to GLOBOCAN, around 90,000 new patients of bladder cancer were diagnosed in North America, in 2020 and this number was anticipated to reach around 136,000 in 2045. So, this high probability of increasing incidence of the disease in the region provides high opportunity for the growth of the market in the near future.

Meanwhile, the market of Asia Pacific is projected to grow with a substantial pace as the region has witnessed a large number of population with urothelial cancer. Along with the high rate of research activities and increased drug approvals, the rising government initiatives for public awareness campaign related to various types of cancer is pushing the market growth in the region.

Get Free Sample Report

Segments

The global urothelial cancer drugs market has been segmented on the basis of

Treatments

• Chemotherapy
• Immunotherapy

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Regeneron Pharmaceuticals, Inc.
• Pfizer, Inc.
• GlaxoSmithKline plc.
• Genentech
• Bristol-Myers Squibb Co.
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck KGaA
• Eli Lilly and Co.
• AstraZeneca
• Exelixis, Inc.
• Immunomedics
• UroGen Pharma, Inc.
• Johnson & Johnson Services, Inc.
• Astellas Pharma US, Inc.
• Janssen Biotech, Inc.
• Sitka Biopharma
• Sesen Bio

Competitive Landscape

Key players competing in the global urothelial cancer drugs market are Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; GlaxoSmithKline plc.; Genentech; Bristol-Myers Squibb Co.; Sanofi; F. Hoffmann-La Roche Ltd; Novartis AG; Merck KGaA; Eli Lilly and Co.; AstraZeneca; Exelixis, Inc.; Johnson & Johnson Services, Inc.; Immunomedics; UroGen Pharma, Inc.; Astellas Pharma US, Inc.; Janssen Biotech, Inc.; Sitka Biopharma; and Sesen Bio.

Merck and AstraZeneca are anticipated to top the market in 2023, which is bolstered by approvals of Keytruda + chemotherapy and Imfinzi + tremelimumab regimens in early stages of treatment for both chemo-eligible and chemo-ineligible cases.